Results 101 to 110 of about 22,935 (284)
, 1989 peer reviewedAccording to the modern pathophysiological understanding of type 2 diabetes and the mechanisms of sulfonylurea action, combined insulin-sulfonylurea therapy appears to be an interesting alternative for treating diabetic patients with ...
Scheen, André, Lefebvre, Pierre
core +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims The association between glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) use and the development of bowel obstruction/ileus remains unclear, and evidence for specific bowel obstruction/ileus subtypes remains limited. We examined the association between GLP‐1RA use and the incidence of bowel obstruction/ileus subtypes across different ...
Yuichiro Matsuo +3 more
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims Chronic kidney disease (CKD) is a major complication of type 2 diabetes mellitus (T2DM), driven in part by oxidative stress and the accumulation of advanced glycation end products (AGEs). Oleanolic acid (OA), a natural triterpene present in olive‐derived matrices, may modulate AGE metabolism.
Aída García‐González +14 more
wiley +1 more source
, 2008 OBJECTIVE - Neonatal diabetes can result from mutations in the Kir6.2 or sulfonylurea receptor 1 (SUR1) subunits of the ATP-sensitive K+ channel. Transfer from insulin to oral sulfonylureas in patients with neonatal diabetes due to Kir6.2 mutations is ...
Neonatal Diabetes International Collaborative Group +27 more
core +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims To identify low‐ and high‐risk intervals for major adverse cardiovascular events (MACE) and all‐cause mortality according to lipid ratios in adults with Type 2 diabetes mellitus (T2DM), stratified by sex. Materials and Methods We used primary care electronic health records from the Spanish National Health Service including 303 199 adults ...
Enrique Carretero‐Anibarro +5 more
wiley +1 more source
Counterpoint: A Diabetes Outcome Progression Trial (ADOPT): Good for Sulfonylureas?
A Diabetes Outcome Progression Trial (ADOPT) was conceived in the hope that the seemingly inexorable decline in islet B-cell function described with metformin, sulfonylureas, and insulin in the UK Prospective Diabetes Study (UKPDS) might be stopped or ...
Home P, Al-Ozairi E, Sibal S
core +5 more sources
Sulfonylureas and Risk of Falls and Fractures: A Systematic Review
, 2013 BACKGROUND: Sulfonylureas have been linked to increased risk of hypoglycemia. Hypoglycemia may lead to falls, and falls may lead to fracture. However, studies quantifying the association between sulfonylureas and fractures are sparse and yield ...
Pagliasotti, Caleb +5 more
core +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Background and Aims People with diabetes and chronic kidney disease (CKD) may be at increased risk of iatrogenic hypoglycaemia. We compared rates of sensor‐detected (SDH) and person‐reported hypoglycaemia (PRH) in people with insulin‐treated Type 2 diabetes (T2D) with and without CKD in the Hypo‐METRICS study.
Julie M. B. Brøsen +39 more
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Objective Treatment response in type 2 diabetes (T2D) varies widely among individuals. This study aimed to quantify the contributions of clinical characteristics and genetic predisposition as measured through partitioned polygenic risk scores (pPRS) to variation in glycemic response to glucose‐lowering therapies.
S. Garg +4 more
wiley +1 more source
, 1973 The influence of two sulfonylureas, tolbutamide and glibenclamide, on the secretion of rat pancreatic immunoreactive insulin (IRI), glucagon (IRG), and intestinal glucagon-like immunoreactivity (GLI) was studied in vitro.
P. M. Crockford, S. A. Addah, P. Powell
core +1 more source